Repron Therapeutics

Building medicines around differentiated insights into RNA regulation in cancer.

Repron Therapeutics is developing an innovative oncology platform based on engineered synthetic factors designed to silence oncogenic transcription factors driving tumour malignancy and progression.

Its proprietary technology relies on Epigenetic Silencer Factors (ESFs) — rationally engineered proteins that substitute the activation domain of oncogenic factors with epigenetic inhibitory modules. By exploiting the natural DNA-binding specificity of these factors, Repron’s approach converts transcriptional activators into potent silencers, switching off key networks of genes that control tumour cell proliferation, invasiveness, and resistance.

Repron is advancing its synthetic platform to treat aggressive solid tumours where complete surgical resection is unfeasible, aiming to eliminate residual cancer cells at the primary site and prevent localised recurrence or distant metastasis.